Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 itepekimab versus placebo in moderate-to-severe COPD
2020-001818-38Phase 3Active
- Sponsor
- Sanofi
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Itepekimab with Placebo (2 arms). Primary endpoint: Annualized rate of moderate or severe acute exacerbation of COPD. Started Feb 2021; status: active.
02
Drugs
itepekimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2020-001818-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001818-38.